Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer.

Trial Profile

Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2013

At a glance

  • Drugs Anastrozole (Primary) ; Toremifene (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Sep 2013 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000000610).
    • 29 Mar 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top